Open AccessPan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes
Author(s) -
Xiaoxia Chen,
Chunxia Su,
Shengxiang Ren,
Caicun Zhou,
Tao Jiang
Publication year - 2020
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2019.11.52
Subject(s) - immunotherapy , medicine , cancer , cancer immunotherapy , computational biology , oncology , biology
Immune checkpoint inhibitors (ICIs) that target programmed cell death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen-4 (CTLA-4) elicit durable antitumor responses in multiple cancer types. Yet, only a minority of patients could derive clinical benefit (1).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom